Stay updated on Upadacitinib vs Methotrexate in MTX-Naive RA: Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib vs Methotrexate in MTX-Naive RA: Clinical Trial page.

Latest updates to the Upadacitinib vs Methotrexate in MTX-Naive RA: Clinical Trial page
- Check5 days agoChange DetectedThe page no longer displays some MedlinePlus-related reference text, including a rheumatoid arthritis topic label.SummaryDifference0.0%

- Check12 days agoChange DetectedThe record displays details of the completed Phase 3 rheumatoid arthritis trial comparing upadacitinib with methotrexate, including its design, eligibility criteria, locations, and outcome measures. It also provides study publications, record dates, and information on sharing participant data and study documents.SummaryDifference100%

- Check19 days agoChange DetectedThe ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide banner announces an NIH terminology transition, saying that “Super Intelligence” will be used in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Upadacitinib vs Methotrexate in MTX-Naive RA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib vs Methotrexate in MTX-Naive RA: Clinical Trial page.